Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 10, 2021

BUY
$16.56 - $25.46 $195,275 - $300,224
11,792 New
11,792 $242,000
Q3 2020

Nov 04, 2020

SELL
$16.59 - $24.79 $54,912 - $82,054
-3,310 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $55,806 - $77,586
3,310 New
3,310 $405,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Financial Advocates Investment Management Portfolio

Follow Financial Advocates Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Financial Advocates Investment Management with notifications on news.